Nanobiotix reels in $18.5m tranche from European Investment Bank
Nanobiotix (PAR:NANO.PA) received €16 million ($18.5 million) in the first tranche of a previously-announced non-dilutive loan from the European Investment Bank. The five-year funding deal is designed to support the company’s development of nanoparticle-based cancer therapies. Get the full story at our sister site, Drug Delivery Business News. The post Nanobiotix reels in $18.5m tranche from European Investment Bank appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Funding Roundup Oncology Pharmaceuticals Wall Street Beat nanobiotix Source Type: news

Is the next big step in cancer therapy personalized vaccines?
(University of California - San Diego) Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic. Tamara enrolled in a first-of-its-kind, pilot study at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to boost an anti-tumor immune response. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 12, 2018 Category: Biology Source Type: news

How are pulsed electric fields being used in cancer therapy?
(Mary Ann Liebert, Inc./Genetic Engineering News) Pulsed electric fields are helping fight cancer, whether by inducing tumor cell death or by stimulating the immune system. A comprehensive overview of this developing field is published in the preview issue of Bioelectricity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 11, 2018 Category: Cancer & Oncology Source Type: news

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
(University of Helsinki) Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2018 Category: Cancer & Oncology Source Type: news

The Nobel Prize in Physiology or Medicine 2018 was awarded jointly to James P. Allison and Tasuku Honjo "for their discovery of cancer therapy by inhibition of negative immune regulation."
Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor cells this year's Nobel Laureates have established an entirely new principle for cancer therapy. (Source: World Pharma News)
Source: World Pharma News - October 1, 2018 Category: Pharmaceuticals Tags: Featured Development Research and Development Source Type: news

Medical News Today: Cancer therapy: Bacteria may help shrink tumors
A new phase I clinical trial looks at whether a modified bacterial strain is safe and effective in attacking stubborn, treatment-resistant cancer tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

American and Japanese immunologists are awarded Nobel Medicine Prize
The pair (pictured) were honoured 'for their discovery of cancer therapy by inhibition of negative immune regulation,' the Stockholm-based Nobel Assembly said. (Source: the Mail online | Health)
Source: the Mail online | Health - October 1, 2018 Category: Consumer Health News Source Type: news

Landmark cancer therapy wins Nobel prize for medicine
Two scientists working on immune treatments for cancer have won the 2018 prize for physiology or medicine. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 1, 2018 Category: Consumer Health News Source Type: news

Nobel prize for medicine goes to cancer therapy
Two scientists working on immune treatments for cancer have won the 2018 prize for physiology or medicine. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 1, 2018 Category: Consumer Health News Source Type: news

James P. Allison, Tasuku Honjo Win 2018 Nobel Prize In Physiology Or Medicine
The pair of immunologists won for their discovery of cancer therapy that works by harnessing the body's own immune system. (Source: NPR Health and Science)
Source: NPR Health and Science - October 1, 2018 Category: Consumer Health News Authors: Joe Neel Source Type: news

2018 Nobel Medicine Prize awarded for cancer research
James Allison and Tasuku Honjo won the 2018 Nobel Prize for Physiology or Medicine for discoveries leading to breakthroughs in cancer therapy, the award-giving body said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - October 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Landmark cancer therapy wins Nobel prize
Two scientists working on immune treatments for cancer have won the 2018 prize for physiology or medicine. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 1, 2018 Category: Consumer Health News Source Type: news

The Nobel Prize in medicine awarded to two cancer immunotherapy researchers
The 2018 Nobel Prize in physiology or medicine recognizes James P. Allison and Tasuku Honjo for “their discovery of cancer therapy by inhibition of negative immune regulation.” This is a developing story. It will be updated. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - October 1, 2018 Category: Consumer Health News Authors: The Washington Post Staff Source Type: news

2 Immunologists Win 2018 Nobel Prize In Physiology Or Medicine
James P. Allison, 70, and Tasuku Honjo, 76, won the prize for their discovery of cancer therapy that works by harnessing the body's own immune system. (Source: NPR Health and Science)
Source: NPR Health and Science - October 1, 2018 Category: Consumer Health News Authors: Richard Harris Source Type: news

Medical News Today: Some cancer therapies may avert cardiovascular disease
Drugs that are currently used for cancer may thwart cardiovascular disease, the leading cause of death worldwide, according to a new study. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 29, 2018 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

U.S.-Cuban Biotech Venture Created to Bring New Cancer Therapies to USA U.S.-Cuban Biotech Venture Created to Bring New Cancer Therapies to USA
U.S. and Cuban research institutes said on Wednesday they were creating the first joint U.S.-Cuban biotech venture to be headquartered on the Communist-run island to bring new cancer therapies to U.S. patients.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 27, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

U.S.-Cuban biotech venture created to bring new cancer therapies to USA
U.S. and Cuban research institutes said on Wednesday they were creating the first joint U.S.-Cuban biotech venture to be headquartered on the Communist-run island to bring new cancer therapies to U.S. patients. (Source: Reuters: Health)
Source: Reuters: Health - September 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Chinese Drug Maker Clarifies Development Strategy For Bringing Cancer Drug To The U.S. Market
Given these plans, Chi-Med is open to U.S. partnerships for development of cancer therapies that incorporate fruquintinib. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 26, 2018 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: OTCMKTS:BAYRY NYSE:LLY NASDAQ:HCM Source Type: news

In zebrafish, a way to find new cancer therapies, targeting tumor modulators
This study tested>3,800 drugs in high-throughput fashion and found that retinoic acid, best known as an acne treatment, may be effective for adenoid cystic carcinoma. A clinical trial is now being planned at the Dana-Farber Cancer Institute. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 21, 2018 Category: Biology Source Type: news

Holistic Cancer Therapy and Symptom Management
Professor Judi Fouladbakhsh speaks withCancer Network about evidence-based holistic approaches to cancer care. (Source: CancerNetwork)
Source: CancerNetwork - September 21, 2018 Category: Cancer & Oncology Authors: Judi M. Fouladbakhsh, PhD, RN Source Type: news

Researchers find adult stem cell characteristics in aggressive cancers from different tissues
UCLA researchers have discovered  genetic similarities between the adult stem cells responsible for maintaining and repairing epithelial tissues — which line all of the organs and cavities inside the body — and the cells that drive aggressive epithelial cancers. Their findings could bring about a better understanding of how ag gressive, treatment-resistant cancers develop and progress, and could eventually lead to new drugs for a range of advanced epithelial cancers such as lung, prostate and bladder cancers. The study, led by senior authors Owen Witte and Thomas Graeber, both of the  UCLA E...
Source: UCLA Newsroom: Health Sciences - September 18, 2018 Category: Universities & Medical Training Source Type: news

Controversial chiropractor still posting videos while under investigation
A Halifax-based chiropractor being investigated for online posts that include discredited views on vaccines and cancer therapies continues to share controversial information on social media that is outside her scope of practice. (Source: CBC | Health)
Source: CBC | Health - September 11, 2018 Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news

Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma
A major limitation of targeted cancer therapy is the rapid emergence of drug resistance, which often arises through mutations at or downstream of the drug target or through intrinsic resistance of subpopulations of tumor cells. Medulloblastoma (MB), the most common pediatric brain tumor, is no exception, and MBs that are driven by sonic hedgehog (SHH) signaling are particularly aggressive and drug-resistant. To find new drug targets and therapeutics for MB that may be less susceptible to common resistance mechanisms, we used a developmental phosphoproteomics approach in murine granule neuron precursors (GNPs), the developm...
Source: Signal Transduction Knowledge Environment - September 11, 2018 Category: Science Authors: Purzner, T., Purzner, J., Buckstaff, T., Cozza, G., Gholamin, S., Rusert, J. M., Hartl, T. A., Sanders, J., Conley, N., Ge, X., Langan, M., Ramaswamy, V., Ellis, L., Litzenburger, U., Bolin, S., Theruvath, J., Nitta, R., Qi, L., Li, X.-N., Li, G., Taylor, Tags: STKE Research Articles Source Type: news

Spying on the virus: Development to increase effectiveness of viral cancer therapy
(National University of Science and Technology MISIS) Scientists have learned how to observe the processes of oncolytic viruses in cancer cells in real time. For the first time ever, a group of scientists from NUST MISIS and the University of Calgary (Canada) has managed to apply the technique of intravital microscopy to study the interaction of oncolytic viruses with both tumor and healthy cells of the body. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 7, 2018 Category: International Medicine & Public Health Source Type: news

Alpha Tau Medical raises $29m
Alpha Tau Medical said today it raised $29 million in a private funding round to help support its alpha radiation cancer therapy technology. The round was led by Israeli private equity firm Shavit Capital and joined by global equity crowdfunding platform OurCrowd.com and Medison Pharma venture capital arm Medison Ventures, the Israel-based company said. The round was also joined by Apax Partner founds Ronald Cohen and Alan Patricof, Alpha Tau said. “We are confident that Alpha Tau’s ground-breaking technology can be a game changer in the treatment of cancer. Importantly, under the guidance of an exper...
Source: Mass Device - September 5, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Funding Roundup Alpha Tau Medical Source Type: news

Israeli radiation therapy firm Alpha Tau raises $29 million
Alpha Tau Medical, an Israeli developer of alpha radiation cancer therapy, said on Wednesday it raised $29 million in a private financing round led by  private equity firm Shavit Capital. (Source: Reuters: Health)
Source: Reuters: Health - September 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Deal for NHS to offer exciting new child cancer therapy
The cutting-edge treatment is expensive but could potentially cure children with advanced leukaemia. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 4, 2018 Category: Consumer Health News Source Type: news

NAS/NAM Member and NAS Foreign Associate Share 2018 Nobel Prize in Medicine
NAS/NAM member James P. Allison and NAS foreign associate Tasuku Honjo together have won the 2018 Nobel Prize in Physiology or Medicine"for their discovery of cancer therapy by inhibition of negative immune regulation." (Source: News from the National Academies)
Source: News from the National Academies - September 3, 2018 Category: Science Source Type: news

Liquid Biopsy'Weather Forecast' Can Predict When Tumors Will Return
What if oncologists could predict when cancer therapies will fail? (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 30, 2018 Category: Pharmaceuticals Authors: Victoria Forster, Contributor Tags: NASDAQ:RHHBY NASDAQ:BMY Source Type: news

Stars Rally Together Again For Stand Up To Cancer ’ s Live Broadcast On September 7
LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - August 28, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Only CBS Stand Up To Cancer Source Type: news

New Scale Grades Mutations, Optimizing Targeted Cancer Therapy New Scale Grades Mutations, Optimizing Targeted Cancer Therapy
A new scale for tumor DNA mutations has been developed by the European Society for Medical Oncology, which will simplify and standardize choices for targeted cancer treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Former M.D. Anderson president to retire from cancer center
The third president of the University of Texas M.D. Anderson Cancer Center will retire from the institution Aug. 31, a spokesperson confirmed to Houston Business Journal.   Dr. John Mendelsohn was the president of M.D. Anderson from 1996 to 2011 and remained a faculty member at the center as the director of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, the spokesperson said. He is also a professor in M.D. Anderson’s department of g enomic medicine, per his profile… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 27, 2018 Category: Pharmaceuticals Authors: Jen Para Source Type: news

Former M.D. Anderson president to retire from cancer center
The third president of the University of Texas M.D. Anderson Cancer Center will retire from the institution Aug. 31, a spokesperson confirmed to Houston Business Journal.   Dr. John Mendelsohn was the president of M.D. Anderson from 1996 to 2011 and remained a faculty member at the center as the director of Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, the spokesperson said. He is also a professor in M.D. Anderson’s department of g enomic medicine, per his profile… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 27, 2018 Category: Biotechnology Authors: Jen Para Source Type: news

Novartis wins EU approval for blood cancer therapy Kymriah
Novartis has received European approval for Kymriah, its gene-modifying therapy for blood cancer, but said its introduction would vary from country to country as the Swiss drugmaker works out payment details and builds manufacturing capacity. (Source: Reuters: Health)
Source: Reuters: Health - August 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes Can Develop in Cancer Patients Treated With Checkpoint Inhibitors
Cancer treatment has been transformed by the use of monoclonal antibodies (mAbs) that block immune inhibitory ligands CTLA-4 and PD-1, known as immune checkpoint inhibitors (CPIs). With these options for treatment of cancers that are resistant to conventional cancer therapies, the life expectancy of patients with melanoma, lung cancer, renal cell carcinoma, and other cancers, has shown significant improvement. However, according to the journal Diabetes, some patients experience adverse effects. One percent of patients treated with anti –PD-1 or –PD-L1 CPIs develop diabetes.08/22/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 22, 2018 Category: Urology & Nephrology Source Type: news

Veterans get inappropriate prostate imaging outside VA
Veterans who seek care for low-risk prostate cancer receive more imaging that...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Multiparametric MRI aids in prostate cancer follow-up SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment MRI-based risk model improves prostate cancer detection (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 17, 2018 Category: Radiology Source Type: news

Eileen Parkes on Why Cancer Researchers Are Excited About STING Agonists
ONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2018 Category: Cancer & Oncology Authors: Eileen Parkes, MD, PhD Source Type: news

Nanoparticle therapy could deliver double blow to cancer
(University of East Anglia) A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon.Using nanoparticles to get drugs directly into a tumor is a growing area of cancer research. The technology developed at UEA is the first of its kind to use nanoparticles to deliver two drugs in combination to target cancer cells. The therapy has been shown to make breast cancer and prostate cancer tumors more sensitive to chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 9, 2018 Category: International Medicine & Public Health Source Type: news

UCLA Health joins nationwide clinical trial for acute myeloid leukemia
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - August 8, 2018 Category: Universities & Medical Training Source Type: news

Regeneron partners with bluebird on cancer therapies, invests $100 million
The company will use its VelociSuite platform in order to help find human antibodies as well as T cell receptors and bluebird will contribute its expertise in gene transfer and cell therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 7, 2018 Category: Pharmaceuticals Source Type: news

Researchers use microparticles for targeted delivery of brain cancer therapy
Credit: Christine Daniloff/MIT A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to check for a mutation linked to glioma and implanted microparticles that slowly elute drug over the course of several days or even weeks to treat the brain cancer. Get the full story at our sister site, ...
Source: Mass Device - August 7, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Brigham & Women's Hospital Massachusetts General Hospital Massachusetts Institute of Technology Source Type: news

Sensor could help doctors select effective cancer therapy
(Massachusetts Institute of Technology) MIT chemical engineers have developed a sensor that lets them see hydrogen peroxide inside cancer cells and determine whether they are responding to drugs that affect redox signaling. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 7, 2018 Category: Cancer & Oncology Source Type: news

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies
Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer. (Source: Reuters: Health)
Source: Reuters: Health - August 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Medical News Today: New drug may improve liver cancer therapy
Hepatocellular carcinoma (liver cancer) is fast growing, has poor survival rates, and has inefficient current treatments. Can they be improved? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 6, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Mushrooms of the Far East hold promise for the anti-cancer therapy
Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities and low-toxicity. These compounds may offer new avenues for oncology, providing us with either stand-alone alternatives to chemotherapy, chemopreventive medicines, or drugs to be used in combination with other therapies. (Source: World Pharma News)
Source: World Pharma News - August 3, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

AI speeds up radiation therapy planning
With a new artificial intelligence (AI) algorithm, planning for radiation therapy...Read more on AuntMinnie.comRelated Reading: Can AI best quantitative MRI in prostate lesions? Breast cancer follow-up imaging varies widely SNMMI: Early prostate cancer therapy extends lives SNMMI: Fluciclovine-PET changes prostate treatment SNMMI: New therapy aids patients with neuroendocrine tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 2, 2018 Category: Radiology Source Type: news

Mushrooms of the far east hold promise for the anti-cancer therapy
(Far Eastern Federal University) Mushrooms from the Far East area contain the natural chemical compounds, which could be used for the design of the novel drugs with highly specific anti-tumor activities and low-toxicity. These compounds may offer new avenues for oncology, providing us with either stand-alone alternatives to chemotherapy, chemopreventive medicines, or drugs to be used in combination with other therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 2, 2018 Category: Cancer & Oncology Source Type: news

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers
This research article found patients who received CM were more likely to refuse additional conventional cancer treatment (surgery/chemo or radio or hormone therapy) and had higher risk of death. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 1, 2018 Category: Consumer Health News Source Type: news

Novel drug cocktails strengthen targeted cancer therapies while lessening side effects
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Mount Sinai researchers have discovered that certain drug cocktails help targeted therapies attack cancer more efficiently while lessening common side effects, according to a study published today in Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 1, 2018 Category: Cancer & Oncology Source Type: news

Medical researchers from MSU suggested a new approach of targeted cancer therapy
(Lomonosov Moscow State University) A team from the Faculty of Medicine, MSU has analysed a link between the p53 protein, tumor dissemination and 'cell suicide' and discussed possible approaches to predict metastases development and their treatment. They also discussed new chemical compounds that might influence the process of metastasis. The study was supported by a grant from Russian Science Foundation (RSF). The results were published in the Cancers journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2018 Category: International Medicine & Public Health Source Type: news